Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis

Completed · Phase 3

Conditions studied: Atopic Dermatitis

In brief

Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of pimecrolimus cream will be evaluated in Japanese adult patients with atopic dermatitis. This study is a 6-month extension study following core study. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

Key facts

Study ID

NCT00232011

Run by

Novartis

People needed

160

Starts

2004-05-01

Expected to finish

2005-05-01

Last updated by the study team

2007-12-17

Who can join

Age: 16 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who had completed the core study and whose participation in this study was considered appropriate as judged by the investigator
• Patients who had given written informed consent to participation in this study

You may not qualify if…

• Patients who failed in treatment compliance in the core study
• Patients who had a major violation of the protocol in the core study

Where it is running

• This study is not being conducted in the United States — Various Cities, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.